| Effectiveness and tolerability of benepali in rheumatoid arthritis patients switched from enbrel S Dyball, V Hoskins, S Christy-Kilner, S Haque ARTHRITIS & RHEUMATOLOGY 69, 2017 | 19 | 2017 |
| Predicting progression from undifferentiated connective tissue disease to definite connective tissue disease: a systematic review and meta-analysis S Dyball, M Rodziewicz, C Mendoza-Pinto, IN Bruce, B Parker Autoimmunity Reviews 21 (11), 103184, 2022 | 10 | 2022 |
| Lupus clinical trial eligibility in a real-world setting: results from the British Isles Lupus Assessment Group-Biologics Register (BILAG-BR) S Dyball, S Collinson, E Sutton, EM McCarthy, IN Bruce, B Parker Lupus Science & Medicine 8 (1), e000513, 2021 | 10 | 2021 |
| Early infection risk in patients with systemic lupus erythematosus treated with rituximab or belimumab from the British Isles Lupus Assessment Group Biologics Register (BILAG … M Rodziewicz, S Dyball, M Lunt, S McDonald, E Sutton, B Parker, ... The Lancet Rheumatology 5 (5), e284-e292, 2023 | 8 | 2023 |
| Acute paraquat exposure impairs colonic motility by selectively attenuating nitrergic signalling in the mouse L Diss, S Dyball, T Ghela, J Golding, R Morris, S Robinson, R Tucker, ... Autonomic Neuroscience 195, 8-15, 2016 | 7 | 2016 |
| PROFILING RHEUMATOID ARTHRITIS BIOSIMILAR SWITCHERS: DATAFROM THE BRITISH SOCIETY FOR RHEUMATOLOGY BIOLOGICS REGISTER FOR RHEUMATOID ARTHRITIS D De Cock, S Dyball, L Kearsley-Fleet, K Watson, K Hyrich Rheumatology 57, 2018 | 4 | 2018 |
| PS8: 154 Therapeutic and cardiovascular disease burden in undifferentiated connective tissue disease and systemic lupus erythematosus: results from the lupus extended … S Dyball, J Reynolds, IN Bruce, B Parker Lupus Science & Medicine 5 (Suppl 1), 2018 | 3 | 2018 |
| Determinants of health-related quality of life across the spectrum of connective tissue diseases using latent profile analysis: results from the LEAP cohort S Dyball, JA Reynolds, AL Herrick, S Haque, H Chinoy, E Bruce, S Naz, ... Rheumatology 62 (8), 2673-2682, 2023 | 2 | 2023 |
| Ianalumab in Sjögren's syndrome: what can we learn from lupus trials? S Dyball, B Parker, IN Bruce The Lancet 400 (10355), 807-808, 2022 | 2 | 2022 |
| 231 Pre-treatment anxiety and depression levels are correlated with less improvement in self-reported disease activity in rheumatoid arthritis patients treated with biological … S Dyball, L Cordingley, JD Isaacs, G Wilson, A Morgan, K Hyrich, D Plant, ... Rheumatology 57 (suppl_3), key075. 455, 2018 | 2 | 2018 |
| Predictors and prognostic factors influencing outcomes of anti-CD20 monoclonal antibodies in systemic lupus erythematosus: A systematic review update M Rodziewicz, C Mendoza-Pinto, S Dyball, P Munguía-Realpozo, ... Seminars in Arthritis and Rheumatism 65, 152346, 2024 | 1 | 2024 |
| An imperfect world: assessing safety of biological treatments in systemic lupus erythematosus. Comment on the article by Materne et al M Rodziewicz, S Dyball, S Achieng, SR Brix, B Parker, IN Bruce Arthritis & Rheumatology 76 (2), 315-316, 2024 | 1 | 2024 |
| OP0013 APPLYING STANDARD CLASSIFICATION CRITERIA EXCLUDES UP TO A HALF OF ALL PATIENTS FROM CONNECTIVE TISSUE DISEASES (CTD) CLINICAL TRIALS S Dyball, M Rodziewicz, AV Madenidou, J Reynolds, A Herrick, S Haque, ... Annals of the Rheumatic Diseases 82 (Suppl 1), 9-9, 2023 | 1 | 2023 |
| 241 Profiling rheumatoid arthritis biosimilar switchers: datafrom the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis D De Cock, S Dyball, L Kearsley-Fleet, K Watson, K Hyrich, ... Rheumatology 57 (suppl_3), key075. 465, 2018 | 1 | 2018 |
| POS1320 FUNCTIONAL MAPPING OF AUTOIMMUNE PATIENTS BASED ON SERUM IMMUNE COMPLEXES REVEALS A COMMON TLR7/8 ENDOTYPE S Hawtin, S Dyball, C André, S Appenzeller, B Bannert, H Brunner, ... Annals of the Rheumatic Diseases 83 (Suppl 1), 1124-1124, 2024 | | 2024 |
| OP0149 DISCORDANCE IN CLINICAL RESPONSE AND PATIENT-REPORTED OUTCOMES IN MODERATE-SEVERE SLE: RESULTS FROM THE BRITISH ISLES LUPUS ASSESSMENT GROUP-BIOLOGICS REGISTER (BILAG-BR) S Dyball, M Rodziewicz, E Sutton, B Parker, IN Bruce Annals of the Rheumatic Diseases 83 (Suppl 1), 158-159, 2024 | | 2024 |
| POS0537 GLOBAL PERSPECTIVES ON GLUCOCORTICOID MANAGEMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM THE LUPHPOS SURVEY S Dyball, CS Santos, KA Chandwar, E Chessa, M Mosca Annals of the Rheumatic Diseases 83 (Suppl 1), 951-951, 2024 | | 2024 |
| OP0043 THE EFFECTIVENESS OF RITUXIMAB IN THE REAL-WORLD TREATMENT OF NEUROPSYCHIATRIC SLE: RESULTS FROM THE BRITISH ILES LUPUS ASSESSMENT GROUP BIOLOGICS REGISTER (BILAG-BR) M Rodziewicz, S Dyball, T David, E Sutton, B Parker, IN Bruce Annals of the Rheumatic Diseases 83 (Suppl 1), 137-138, 2024 | | 2024 |
| Clinical trial eligibility of a real-world connective tissue disease cohort: results from the LEAP cohort S Dyball, AV Madenidou, M Rodziewicz, JA Reynolds, AL Herrick, ... Seminars in arthritis and rheumatism, 152463, 2024 | | 2024 |
| Listening to patients, for the patients: The COVAD Study—Vision, organizational structure, and challenges M Joshi, N Darooka, S Saha, S Dyball, P Sen, P Yaadav, M Javaid, ... International Journal of Rheumatic Diseases 27 (5), e15161, 2024 | | 2024 |
